Table 1.
Pathophysiology and biology |
Biology of the SARS-CoV-2 viral spike protein |
Chloroquine and its potential role in COVID-19 |
Hyperinflammation in critical illness and its application to coronavirus infections |
Exploring concerns about the renin-angiotensin system in COVID-19 |
Antibody-dependent enhancement in COVID-19 |
Respiratory failure and critical care |
Is COVID-19 ARDS? |
Prone position in the nonintubated patient |
Use of inhaled nitric oxide in ARDS and potential role in COVID-19 |
Exploring the role of disordered coagulation in ARDS in COVID-19 |
Review of PEEP optimization and recruitment maneuvers in ARDS |
Revisiting investigational therapies for ARDS in the setting of COVID-19 |
The role of early tracheostomy in patients with respiratory failure resulting from COVID-19 |
Postextubation stridor in COVID-19 |
Fluid management in ARDS |
Clinical care |
Rationale and evidence for convalescent plasma use in COVID-19 |
COVID-19 presenting with GI disease |
Current data regarding myocarditis and COVID-19 |
Utility of CT scans in patients with COVID-19 |
Procalcitonin in SARS-CoV-2 |
Reviews of recent publications |
Summary and analysis of recent lopinavir/ritonavir trial in COVID-19 |
Distillation of literature on risk factors for COVID-19 |
Analysis and comparison of recently published case series of patients with COVID-19 |
Evidence for remdesivir use |
Definition of abbreviations: ARDS = acute respiratory distress syndrome; COVID-19 = coronavirus disease; CT = computed tomography; GI = gastrointestinal; PEEP = positive end-expiratory pressure; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.